|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Racl in human breast cancer: Ovcrexpression, mutation analysis, and characterization of a new isoform, Racl b 显示文摘 | Sehnelzer A Prechtel D Knaus U Dehne K Gerhard M Graeff H | 2000 | Oncogene2000，19，26： | 1 |
| 2 | Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer显示文摘 | SCHMALFELDT B PRECHTEL D HARTING K | 2001 | Clin Cancer Res2001，7，8： | 1 |
| 3 | Infection of mature dendritic cells with herpes simplex virus type 1 dramatically reduces lymphoid chemokine-mediatedmigration显示文摘 | Prechtel A T Turza N M Kobelt D J | 2005 | J Gen Virol2005，86，6： | 1 |
| 4 | Increased expression of matrix metalloproteinases (MMP) - 2, MMP - 9, and the urokinase - type plasminogen activator is associated with progression from be- nign to advanced ovarian cancer 显示文摘 | Schmalfeldt B Prechtel D Hatrting K | 2001 | Clin Cancer Res2001，7，8： | 1 |
| 5 | c-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu 显示文摘 | Lengyel E Prechtel D Resau JH | 2005 | Int J Cancer2005，113，4： | 1 |
| 6 | Increased expression of matrix metalloproteinases (MMP)-2,MMP -9,and the urokinase -type plasminogen activator is associated with progression from benign to advanced ovarian cancer 显示文摘 | Schmalfeldt B Prechtel D Harting K | 2001 | Clin Cancer Res2001，7，8： | 1 |
| 7 | Increased expression of matrix metalloproteinases-2,-9 and the urokinse-type plasminogen activator is associated with progression from benign to advanced ovarian cancer显示文摘 | Schrnalfeldt B Prechtel D Harting K | 2001 | Clin Cancer Res2001，7，8： | 1 |
| 8 | Increased expression of matrix metalloproteinase( MMP-2 ), MMp-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer 显示文摘 | Schmalfeldt B Prechtel D Harting K | 2001 | Clin Cancer Res2001，7，8： | 1 |
| 9 | Increased expres- sion of matrix metalloproteinases (MMP) -2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer 显示文摘 | Sehmalfeldt B Prechtel D Harting K | 2001 | Clirt Cancer2001，7，8： | 1 |
| 10 | CD83 knockdown in monocyte-derived dendritic cells by small interfering RNA leads to a diminished T cell stimulation显示文摘 | Prechtel AT Turza N Theodoridis M | 2010 | Cell Cycle2010，15，： | 1 |
| 11 | Rac l in human breast cancer:overexpression,mutation analysis,and characterization of a new isoform,Rac lb显示文摘 | Schnelzer A Prechtel D Knaus U | 2000 | Oncogene2000，19，26： | 1 |
| 12 | CD83: an update on func- tions and prospects of the maturation marker of dendritic cells显示文摘 | Prechtel AT Steinkasserer A | 2007 | Arch Dermatol Res2007，299，2： | 1 |
| 13 | CD83: an update on functions and prospects of the maturation marker of dendritic cells显示文摘 | Prechtel A T Steinkasserer A | 2007 | Arch Dermatoi Res2007，299，： | 1 |
| 14 | CD83: an update on functions and prospects of the maturation marker of dendritic cells显示文摘 | Prechtel AT Steinkasserer A | 2007 | Arch Derma?tol Hes2007，299，2： | 1 |
| 15 | CD83 knokdown in monocyte derived dendritic cells by small interfering RNA leads to diminished T cell stimulation显示文摘 | Prechtel AT Turza N Theodoridis M | 2010 | J Cell Cycle2010，159，9： | 1 |
| 16 | Increased expression of matrix metalloproteinases (MMP)-2,MMP-9,and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer显示文摘 | Schmalfeldt B Prechtel D Harting K | 2001 | Clin Cancer Res2001，7，8： | 1 |
| 17 | C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu显示文摘 | Lengyel E Prechtel D Resau JH | 2005 | Int J Cancer2005，113，4： | 1 |
| 18 | Increased expression of matrix metalloproteinases (MMP) -2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer 显示文摘 | Schmalfeldt B Prechtel D Harting K | 2001 | Clin Cancer Res2001，7，8： | 1 |
| 19 | Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer显示文摘 | Schmalfeldt B Prechtel D Harting K | 2001 | Clin Cancer Res2001，7，8： | 1 |
| 20 | Increased expression of matrix metalloproteinases (MMP)-2,MMP-9,and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer显示文摘 | Schmalfeldt B Prechtel D Hharting K | 2001 | Clin Cancer Res2001，7，8： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员